Identification and Validation of Ferroptosis-Related Subtypes and a Predictive Signature in Hepatocellular Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018, GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Marasco G, Colecchia A, Colli A, et al. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. J Hepatol. 2019;70. doi:10.1016/j.jhep.2018.10.022
   Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE), a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet. 2017;389:56–66. doi:10.1016/s0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• Foerster F, Galle PR. The current landscape of clinical trials for systemic treatment of HCC. Cancers. 2021;13:1962. doi:10.3390/cancers13081962
   PubMed Web of Science ®Google Scholar
• Kudo M. Scientific rationale for combination immunotherapy of hepatocellular carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 antibodies. Liver Cancer. 2019;8. doi:10.1159/000503254
   Web of Science ®Google Scholar
• Pinto Marques H, da Silva G, De Martin S, Agopian E, Martins PN. Emerging biomarkers in HCC patients, Current status. Int J Surg. 2020;82:70–76. doi:10.1016/j.ijsu.2020.04.043
   Web of Science ®Google Scholar
• Dixon SJ, Lemberg K, Lamprecht M, et al. Ferroptosis, an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–1072. doi:10.1016/j.cell.2012.03.042
   PubMed Web of Science ®Google Scholar
• Yang WS, SriRamaratnam R, Welsch M, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317–331. doi:10.1016/j.cell.2013.12.010
   PubMed Web of Science ®Google Scholar
• Lachaier E, Louandre C, Godin C, et al. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res. 2014;34:6417–6422.
   PubMed Web of Science ®Google Scholar
• Sun J, Zhou C, Zhao Y, et al. Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation. Redox Biol. 2021;41:101942. doi:10.1016/j.redox.2021.101942
   PubMed Web of Science ®Google Scholar
• Chang WT, Bow Y-D, Fu P-J, et al. A marine terpenoid, heteronemin, induces both the apoptosis and ferroptosis of hepatocellular carcinoma cells and involves the ROS and MAPK pathways. Oxid Med Cell Longev. 2021;2021:1–12. doi:10.1155/2021/7689045
   Web of Science ®Google Scholar
• Yang M, Wu X, Hu J, et al. COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma. J Hepatol. 2022;76:1138–1150. doi:10.1016/j.jhep.2022.01.009
   PubMed Web of Science ®Google Scholar
• Gao R, Kalathur RKR, Coto‐Llerena M, et al. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med. 2021;13:e14351. doi:10.15252/emmm.202114351
   PubMed Web of Science ®Google Scholar
• Steuer CE, Ramalingam SS. Tumor mutation burden, leading immunotherapy to the era of precision medicine? J Clin Oncol. 2018;36:631–632. doi:10.1200/jco.2017.76.8770
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee C-H, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202–206. doi:10.1038/s41588-018-0312-8
   PubMed Web of Science ®Google Scholar
• McNamara MG, Jacobs T, Lamarca A, et al. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. Cancer Treat Rev. 2020;89:102084. doi:10.1016/j.ctrv.2020.102084
   PubMed Web of Science ®Google Scholar
• Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens, building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125:3413–3421. doi:10.1172/jci80008
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598–2608. doi:10.1158/1535-7163.Mct-17-0386
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79:4557–4566. doi:10.1158/0008-5472.Can-18-3962
   PubMed Web of Science ®Google Scholar
• Wang W, Green M, Choi JE, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270–274. doi:10.1038/s41586-019-1170-y
   PubMed Web of Science ®Google Scholar
• Tang D, Chen X, Kang R, Kroemer G. Ferroptosis, molecular mechanisms and health implications. Cell Res. 2021;31:107–125. doi:10.1038/s41422-020-00441-1
   PubMed Web of Science ®Google Scholar
• Xu H, Ye D, Ren M, Zhang H, Bi F. Ferroptosis in the tumor microenvironment, perspectives for immunotherapy. Trends Mol Med. 2021;27:856–867. doi:10.1016/j.molmed.2021.06.014
   PubMed Web of Science ®Google Scholar
• Zhou N, Bao J. FerrDb, a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database. 2020;2020. doi:10.1093/database/baaa021
   Google Scholar
• Wilkerson MD, Hayes DN. ConsensusClusterPlus, a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26:1572–1573. doi:10.1093/bioinformatics/btq170
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA, gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48–61. doi:10.1016/j.cell.2014.12.033
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4. doi:10.1038/ncomms3612
   Web of Science ®Google Scholar
• Locati M, Deuschle U, Massardi ML, et al. Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J Immunol. 2002;168:3557–3562. doi:10.4049/jimmunol.168.7.3557
   PubMed Web of Science ®Google Scholar
• Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory T cells in cancer. Adv Cancer Res. 2010;107:57–117. doi:10.1016/s0065-230x(10)07003-x
   PubMed Web of Science ®Google Scholar
• Li P, Wang N, Zhang Y, Wang C, Du L. HLA-G/sHLA-G and HLA-G-bearing extracellular vesicles in cancers, potential role as biomarkers. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.791535
   Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–174. doi:10.1038/nri2506
   PubMed Web of Science ®Google Scholar
• Chen KJ, Lin SZ, Zhou L, et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One. 2011;6. doi:10.1371/journal.pone.0024671
   Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma, ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238–iv255. doi:10.1093/annonc/mdy308
   PubMed Web of Science ®Google Scholar
• Bruix J, Cheng A-L, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma, Analysis of two Phase III studies. J Hepatol. 2017;67:999–1008. doi:10.1016/j.jhep.2017.06.026
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224), a non-randomised, open-label Phase 2 trial. Lancet Oncol. 2018;19:940–952. doi:10.1016/s1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040), an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502. doi:10.1016/s0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Sato M, Kusumi R, Hamashima S, et al. The ferroptosis inducer erastin irreversibly inhibits system x(c)- and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells. Sci Rep. 2018;8. doi:10.1038/s41598-018-19213-4
   Web of Science ®Google Scholar
• Sui X, Zhang R, Liu S, et al. RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer. Front Pharmacol. 2018;9. doi:10.3389/fphar.2018.01371
   Web of Science ®Google Scholar
• Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35:830–849. doi:10.1016/j.ccell.2019.04.002
   PubMed Web of Science ®Google Scholar
• Pottier C, Wheatherspoon A, Roncarati P, et al. The importance of the tumor microenvironment in the therapeutic management of cancer. Expert Rev Anticancer Ther. 2015;15:943–954. doi:10.1586/14737140.2015.1059279
   PubMed Web of Science ®Google Scholar
• Lugade AA, Kalathil S, Miller A, Iyer R, Thanavala Y. High immunosuppressive burden in advanced hepatocellular carcinoma patients, Can effector functions be restored? Oncoimmunology. 2013;2:e24679. doi:10.4161/onci.24679
   PubMed Web of Science ®Google Scholar
• Melief CJ. Mutation-specific T cells for immunotherapy of gliomas. N Engl J Med. 2015;372:1956–1958. doi:10.1056/NEJMcibr1501818
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8 + cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234:8509–8521. doi:10.1002/jcp.27782
   PubMed Web of Science ®Google Scholar
• Gwalani LA, Orange JS. Single degranulations in NK cells can mediate target cell killing. J Immunol. 2018;200:3231–3243. doi:10.4049/jimmunol.1701500
   PubMed Web of Science ®Google Scholar
• Barry KC, Hsu J, Broz ML, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018;24:1178–1191. doi:10.1038/s41591-018-0085-8
   PubMed Web of Science ®Google Scholar
• Morvan MG, Lanier LL. NK cells and cancer, you can teach innate cells new tricks. Nat Rev Cancer. 2016;16:7–19. doi:10.1038/nrc.2015.5
   PubMed Web of Science ®Google Scholar
• Teng CF, Wang T, Wu T-H, et al. Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model. Ther Adv Med Oncol. 2020;12:175883592092203. doi:10.1177/1758835920922034
   Web of Science ®Google Scholar
• Kabelitz D, Serrano R, Kouakanou L, Peters C, Kalyan S. Cancer immunotherapy with γδ T cells, many paths ahead of us. Cell Mol Immunol. 2020;17. doi:10.1038/s41423-020-0504-x
   Web of Science ®Google Scholar
• Shi C, Chen Y, Chen Y, Yang Y, Bing W, Qi J. CD4(+) CD25(+) regulatory T cells promote hepatocellular carcinoma invasion via TGF-β1-induced epithelial-mesenchymal transition. Onco Targets Ther. 2019;12. doi:10.2147/ott.S172417
   Web of Science ®Google Scholar
• Zhao F, Korangy F, Greten TF. Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma. Dig Dis. 2012;30:477–482. doi:10.1159/000341695
   PubMed Web of Science ®Google Scholar
• Hao X, Sun G, Zhang Y, et al. Targeting immune cells in the tumor microenvironment of HCC, new opportunities and challenges. Front Cell Dev Biol. 2021;9. doi:10.3389/fcell.2021.775462
   Web of Science ®Google Scholar
• Zhang Z, Ma L, Goswami S, et al. Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma. Oncoimmunology. 2019;8:e1571388. doi:10.1080/2162402x.2019.1571388
   PubMed Web of Science ®Google Scholar
• Wang K, Nie X, Rong Z, et al. B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice. Int J Cancer. 2017;141:1201–1214. doi:10.1002/ijc.30823
   PubMed Web of Science ®Google Scholar
• Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut. 2017;66:342–351. doi:10.1136/gutjnl-2015-310814
   PubMed Web of Science ®Google Scholar
• Gao Q, Qiu S-J, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586–2593. doi:10.1200/jco.2006.09.4565
   PubMed Web of Science ®Google Scholar
• Yao W, He J-C, Yang Y, et al. The prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma, a systematic review and meta-analysis. Sci Rep. 2017;7. doi:10.1038/s41598-017-08128-1
   Web of Science ®Google Scholar